Access TOC
Download Brochure
January 2025
The global allergy immunotherapy market size is calculated at USD 1.95 billion in 2024, grew to USD 2.12 billion in 2025, and is projected to reach around USD 4.50 billion by 2034. The market is expanding at a CAGR of 8.73% between 2025 and 2034. The increasing incidences of allergies, growing awareness, and technological advancements drive the market.
Unlock Infinite Advantages: Subscribe to Annual Membership
Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a treatment to develop a tolerance for allergic reactions. Immunotherapy refers to gradually exposing patients to small amounts of allergens to change the immune system’s response. The allergens are determined by skin or blood tests. Immunotherapy can treat allergies caused by grass pollens, house dust mites, bee venom, and food allergies. It is generally safe and effective for allergic rhinitis, allergic conjunctivitis, allergic forms of asthma, and stinging insects. The different types of immunotherapy used for allergies include allergy shots, sublingual immunotherapy tablets, and medications such as corticosteroids, decongestants and antihistamines.
The increasing incidences of allergic reactions such as environmental and food allergies necessitate their treatment with immunotherapy, boosting the market growth. The growing research and development activities involve developing novel and more effective allergy treatment regimens. The rising awareness about allergies and their type potentiates the demand for their treatment. Advancements in diagnostic techniques help physicians in clinical decision-making, ensuring effective treatment.
Artificial intelligence (AI) has immense potential to revolutionize the market, leading to the latest innovations. AI can be used to identify potential biomarkers involved in allergies. AI-based advanced diagnostic tools can also determine allergen sensitivity and enhance immunotherapy strategies. AI enables researchers to deeply understand allergic diseases and the immunotherapy response associated with the disease. AI helps in developing personalized immunotherapy for allergic patients. It results in developing novel treatments with enhanced efficiency, fewer side effects, and more affordability, leading to better outcomes. AI can also enable allergen mapping and targeted immunotherapy. Additionally, AI can provide real-time patient monitoring data after the administration of allergy immunotherapy.
Increasing Number of Clinical Trials
The increasing number of clinical trials is a major growth factor in the allergy immunotherapy market, owing to the growing research and development activities. The increasing incidences of various types of allergies govern the development of novel immunotherapy regimens. Numerous regulatory agencies necessitate clinical trial data for market approval of a treatment. Hence, several research institutions and pharmaceutical and biotechnology companies conduct clinical trials to study the effect of novel methods and materials on humans. Clinical trials are performed to assess the safety, efficacy, and toxicity profiles of developed immunotherapy. They also give an idea about the effective dosage for humans to administer. The rising collaborations, public-private partnerships, and mergers & acquisitions favor the market growth.
Lack of Allergens
The market faces considerable challenges, including the lack of allergen extracts of known composition and potency for allergy diagnostic testing and AIT treatment. This restricts the development of allergy immunotherapy, hindering market growth.
Advancements in Treatment
The future of the allergy immunotherapy market is promising, driven by the latest advancements in treatment strategies. Several researchers have been focused on developing novel methods and molecules for treating allergies. Allergoids or recombinant allergens based on specific epitopes or joined to immunological adjuvants are under development to overcome challenges during conventional treatment. The latest innovations in recombinant technologies promote the development of recombinant allergens. Novel drug delivery systems are also designed to provide targeted treatment and timely delivery of allergens. Developing tailor-made vaccines containing major allergens or hypoallergenic allergens presents future market growth opportunities. The growing demand for personalized medicines also supports advancements in allergy treatments. Furthermore, the increasing investments in research and development activities lead to the latest innovations.
For instance,
By treatment type, the subcutaneous immunotherapy segment held a dominant presence in the allergy immunotherapy market in 2024. Subcutaneous immunotherapy is allergy shots containing small amounts of allergens that are injected into patients through subcutaneous routes. This type of treatment is generally given for three to five years, depending on the patient’s requirements. It is highly preferred due to its faster onset of action and higher absorption. The segmental growth is attributed to its ability to develop a lasting beneficial effect and prevent new allergies and asthma. Also, it is the only treatment that changes the immune system.
By treatment type, the sublingual immunotherapy segment is expected to grow at the fastest rate in the allergy immunotherapy market during the forecast period. Sublingual immunotherapy refers to administering tablets to allergic patients to keep them under the tongue. They do not require any trained professional to administer the drug, promoting the segment’s growth. In addition, they eliminate injection side effects such as swelling at the injection site and increasing redness.
By type, the tablets segment held the largest share of the allergy immunotherapy market in 2024. Tablets are highly preferred due to the growing demand for home healthcare. They eliminate the need for skilled professionals for drug delivery. The increasing use of sublingual immunotherapy and the rising geriatric population augment the segment’s growth. The geriatric population prefers tablets due to their convenience and non-invasiveness properties. Moreover, they are cheaper than other drug delivery systems, potentiating their demand.
By type, the drops segment is predicted to witness significant growth in the market over the forecast period. The rising incidence of allergic reactions in children and infants boosts the segment’s growth. Drops are easily administered by both pediatric and geriatric populations. Their ease of use increases patient adherence. Drops can also provide tailored treatment dosing to patients based on their conditions or sensitivity.
By allergy type, the allergy rhinitis segment led the global allergy immunotherapy market in 2024. Allergy rhinitis mainly occurs due to environmental allergens such as dust, animal dander, or pollen. It causes inflammation of the nose, resulting in sneezing, congestion, and sore throat. The increasing incidences of allergic rhinitis due to air pollution and climate change fuel the segment’s growth. The prevalence of allergic rhinitis is estimated to be between 5% and 50% globally.
By allergy type, the allergy asthma segment is projected to expand rapidly in the market in the coming years. Allergy asthma is mainly caused by pollen, dust mites, and pet dander. The rising incidences of allergy asthma and growing research and development activities boost the segment’s growth. In the U.S., about 1 in 4 adults and 1 in 5 children have seasonal allergies annually. Approximately 8.3% of Americans, or 24.9 million individuals, suffer from asthma.
By distribution channel, the hospital pharmacy segment registered its dominance over the global allergy immunotherapy market in 2024. Hospital pharmacies provide a wide range of therapeutic options as prescribed by the doctor. The presence of trained professionals and multidisciplinary expertise promotes the segment’s growth. Additionally, the availability of suitable storage space and suitable capital investments drive the segment’s growth. Hospital pharmacies are also preferred due to favorable reimbursement policies. Ongoing clinical trial studies in some hospitals also benefit patients with better treatment outcomes.
By distribution channel, the online pharmacy segment will gain a significant share of the market over the studied period. The rising adoption of smartphones and internet connectivity propel the segment’s growth. Online pharmacies provide a wide range of options for patients, with vast product ranges and costs. It gives the benefit of ordering drugs from the comfort of patient’s homes. They also provide same-day home delivery services and special discount offers.
Europe dominated the global allergy immunotherapy market share by 68% in 2024. The rising prevalence of allergies and favorable regulatory frameworks drive the market. Allergens have been subject to European law since 1989. The increasing number of clinical trials related to allergy immunotherapy positively impacts market growth. Europe registered the highest number of clinical trials on the clinicaltrials.gov website assessing the safety and efficacy of immunotherapy. There were 19 active and recruiting trials as of January 2025. The pharmaceutical companies in Europe also focus on advancing point-of-care diagnostics, allowing for early treatment. Thus, growing research and development activities and increasing investments contribute to the market.
For instance,
North America held a significant share of the allergy immunotherapy market in 2024. The increasing incidences of allergy, technological advancements, and advanced healthcare infrastructure drive the market. According to the Asthma and Allergy Foundation of America, more than 100 million people in the U.S. experience various types of allergies annually. The favorable reimbursement policies also contribute to the market growth. The U.S. government’s Medicare and Medicaid Services provide reimbursement for allergy immunotherapy. A total of 12 million people in the U.S. are enrolled in both Medicaid and Medicare. In Canada, most public drug programs provide coverage for allergen immunotherapy. The new product launches by the U.S. Food and Drug Administration and Health Canada fuel the market.
For instance,
Asia-Pacific is anticipated to grow at the fastest rate in the allergy immunotherapy market during the forecast period. The growing research and development activities, rapid urbanization, and increasing investments drive the market. The favorable government support boosts the market. The Japanese government announced plans to promote allergen immunotherapy by encouraging SLIT utilization for allergic reactions goal to quadruple supply within five years. The Chinese Government is also actively working to create standardized allergen extracts and treatment protocols. It also aims to support research on novel allergens, personalized immunotherapy, and adjuvants. The increasing awareness about effective treatments of allergies also propels the market. Numerous research institutions and organizations conduct seminars, symposiums, and workshops to increase awareness among the general public about allergy immunotherapy.
Luke Barratt, former CEO of Xtract Solutions, commented on acquiring allergy testing and immunotherapy software from ModMed that they have considerable experience entering new markets and quickly evolving the experience of delivering care for its customers. He also added that the company aims to positively impact providers that treat allergies and is excited to join the ModMed team to revolutionize allergy care innovation.
By Treatment Type
By Type
By Allergy Type
By Distribution Channel
By Region
January 2025
January 2025
January 2025
January 2025
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts